Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis

医学 2型糖尿病 内科学 胰岛素 胰高血糖素样肽1受体 糖尿病 低血糖 内分泌学 减肥 兴奋剂 基础(医学) 体重增加 荟萃分析 肥胖 受体 体重
作者
Conrad Eng,Caroline K. Kramer,Bernard Zinman,Ravi Retnakaran
出处
期刊:The Lancet [Elsevier BV]
卷期号:384 (9961): 2228-2234 被引量:367
标识
DOI:10.1016/s0140-6736(14)61335-0
摘要

Combination treatment with a glucagon-like peptide-1 (GLP-1) agonist and basal insulin has been proposed as a treatment strategy for type 2 diabetes that could provide robust glucose-lowering capability with low risk of hypoglycaemia or weight gain. We thus did a systematic review and meta-analysis of randomised controlled trials to assess the effect of this combination treatment on glycaemic control, hypoglycaemia, and weight gain in patients with type 2 diabetes.We systematically searched PubMed, Embase, Cochrane, Web of Knowledge, FDA.gov, and ClinicalTrials.gov for randomised controlled trials (published between Jan 1, 1950, and July 29, 2014; no language restrictions) comparing GLP-1 agonist and basal insulin combination treatment to other anti-diabetic treatments. Our main endpoints were glycaemic control, hypoglycaemia, and change in weight. We assessed pooled data by use of a random-effects model.Of 2905 identified studies, 15 were eligible and were included in our analysis (N=4348 participants). Compared with other anti-diabetic treatments, GLP-1 agonist and basal insulin combination treatment yielded an improved mean reduction in glycated haemoglobin (HbA1c) of -0·44% (95% CI -0·60 to -0·29), an improved likelihood of achieving the target HbA1c of 7·0% or lower (relative risk [RR] 1·92; 95% CI 1·43 to 2·56), no increased relative risk of hypoglycaemia (0·99; 0·76 to 1·29), and a mean reduction in weight of -3·22 kg (-4·90 to -1·54). Furthermore, compared with basal-bolus insulin regimens, the combination treatment yielded a mean reduction in HbA1c of -0·1% (-0·17 to -0·02), with lower relative risk of hypoglycaemia (0·67, 0·56 to 0·80), and reduction in mean weight (-5·66 kg; -9·8 to -1·51).GLP-1 agonist and basal insulin combination treatment can enable achievement of the ideal trifecta in diabetic treatment: robust glycaemic control with no increased hypoglycaemia or weight gain. This combination is thus a potential therapeutic strategy that could improve the management of patients with type 2 diabetes.None.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
123应助daisy采纳,获得10
1秒前
是臻不是真完成签到,获得积分10
1秒前
2秒前
2秒前
SciGPT应助ljs采纳,获得10
2秒前
3秒前
脑洞疼应助hu采纳,获得10
3秒前
aaa发布了新的文献求助30
3秒前
隐形曼青应助爱文字采纳,获得20
3秒前
福同学完成签到,获得积分10
4秒前
徐逊发布了新的文献求助10
4秒前
4秒前
Li完成签到,获得积分10
5秒前
淡淡书文发布了新的文献求助10
5秒前
852应助o30采纳,获得10
5秒前
英吉利25发布了新的文献求助10
5秒前
量子星尘发布了新的文献求助10
5秒前
6秒前
亦承梦发布了新的文献求助10
6秒前
光亮藏鸟发布了新的文献求助10
6秒前
shiwo110完成签到,获得积分10
7秒前
慕青应助LR采纳,获得10
8秒前
淡然的衣完成签到,获得积分10
8秒前
梦梦完成签到,获得积分10
8秒前
爆米花应助莉莉子采纳,获得10
8秒前
9秒前
9秒前
9秒前
二十五发布了新的文献求助10
9秒前
rxb发布了新的文献求助10
9秒前
10秒前
10秒前
11秒前
灵巧土豆完成签到 ,获得积分10
11秒前
12秒前
胖虎应助研友_Z345g8采纳,获得10
12秒前
pluto应助chenhua5460采纳,获得10
12秒前
务实含羞草完成签到 ,获得积分10
12秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969383
求助须知:如何正确求助?哪些是违规求助? 3514211
关于积分的说明 11172730
捐赠科研通 3249476
什么是DOI,文献DOI怎么找? 1794909
邀请新用户注册赠送积分活动 875441
科研通“疑难数据库(出版商)”最低求助积分说明 804827